ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Clinical trials for ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Immunotherapy plus chemo shows promise for Tough-to-Treat endometrial cancer
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (paclitaxel and carboplatin) helps people with advanced or recurrent endometrial cancer live longer without their cancer getting worse. About 813 participants with stage III, IV, or recu…
Matched conditions: ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 08:53 UTC
-
Immunotherapy boost may keep endometrial cancer from returning
Disease control OngoingThis study compares standard radiation therapy alone versus radiation plus the immunotherapy drug pembrolizumab for people with newly diagnosed, early-stage endometrial cancer that has a specific DNA repair problem (dMMR). The goal is to see if adding pembrolizumab lowers the cha…
Matched conditions: ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 08:33 UTC
-
Cancer fear study pulled before starting
Knowledge-focused TerminatedThis study was designed to see if an online mental health program could help women with advanced gynecologic or breast cancer cope with the fear of their cancer coming back. It planned to compare the program to standard educational materials. However, the study was withdrawn befo…
Matched conditions: ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated May 19, 2026 11:59 UTC